Cancer immunotherapy has gained traction in recent years owing to remarkable tumor
clearance in some patients. Despite the notable success of immune checkpoint blockade …

Malignant tumors comprise cancer cells and their surrounding tumor microenvironment
(TME). This environment includes cellular and non-cellular components that collectively form …

Tumor-infiltrating macrophages support critical steps in tumor progression, and their
accumulation in the tumor microenvironment (TME) is associated with adverse outcomes …

Background Patients with metastatic castration-resistant prostate cancer (mCRPC) are
refractory to immune checkpoint inhibitors (ICIs). 1 2 Although prostate cancer is highly …

Pexidartinib is an orally active small molecule inhibitor of tyrosine kinase. It is selective
towards the colony-stimulating factor 1 receptor (CSF1R) and has been approved by FDA for …

Prostate kinase inhibitors can be used to treat metastatic prostate cancer by inhibiting
oncogenic pathways that contribute to tumor growth and spread. Primary and acquired …

Pexidartinib is the first FDA approved drug for adult patients with tenosynovial giant cell
tumor that are not amenable to improvement with surgery. In vitro data has showed …